Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)

70.57
Delayed Data
As of 4:00pm ET
 +7.02 / +11.05%
Today’s Change
49.96
Today|||52-Week Range
140.00
-25.04%
Year-to-Date
Why Alnylam Pharmaceuticals, Inc. Competed Higher Today
3:58pm / MotleyFool.com - Paid Partner Content
Alnylam Pharmaceuticals (ALNY) in Focus: Stock Rises 9.9%
8:51am / Zacks.com - Paid Partner Content
Price Target Changed: Charter Communications (CHTR), Pure Storage (PSTG), Alnylam Pha...
3:17pm / Investing Channel - Paid Partner Content
Better Buy: Alnylam Pharmaceuticals, Inc. vs. Ionis Pharmaceuticals Inc.
May 24 / MotleyFool.com - Paid Partner Content
Alnylam Rises After Ionis Partner Decides Not To Start Phase 3 Study
11:13am / TheStreet.com - Paid Partner Content
Drawing Biopharma Concepts With A Crayon
May 23 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close63.55
Today’s open66.15
Day’s range66.11 - 72.16
Volume3,118,851
Average volume (3 months)1,046,478
Market cap$5.4B
Dividend yield--
Data as of 4:00pm ET, 05/26/2016

Growth & Valuation

Earnings growth (last year)+28.87%
Earnings growth (this year)-43.42%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)-18.72%
P/E ratioNM
Price/Sales192.40
Price/Book4.28

Competitors

 Today’s
change
Today’s
% change
IONSIonis Pharmaceutical...-13.90-39.42%
CRLCharles River Labora...+0.15+0.18%
ICLRICON PLC-0.14-0.20%
PRXLPAREXEL Internationa...+0.02+0.03%
Data as of 4:02pm ET, 05/26/2016

Financials

Next reporting dateAugust 4, 2016
EPS forecast (this quarter)-$1.21
Annual revenue (last year)$41.1M
Annual profit (last year)-$290.1M
Net profit margin-705.83%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
John M. Maraganore
President &
Chief Operating Officer
Barry E. Greene
Corporate headquarters
Cambridge, Massachusetts

Forecasts

Partner Offers

Search for Jobs